These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2577984)

  • 41. Scleroglucan/borax: characterization of a novel hydrogel system suitable for drug delivery.
    Coviello T; Grassi M; Lapasin R; Marino A; Alhaique F
    Biomaterials; 2003 Jul; 24(16):2789-98. PubMed ID: 12711526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrodynamically balanced systems as sustained release dosage forms for propranolol hydrochloride.
    Khattar D; Ahuja A; Khar RK
    Pharmazie; 1990 May; 45(5):356-8. PubMed ID: 2395898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioavailability of oral sustained-release capsules of theophylline.
    Schaaf LJ
    Ann Allergy; 1979 Oct; 43(4):259-60. PubMed ID: 555605
    [No Abstract]   [Full Text] [Related]  

  • 44. Dynamic rheological measurements and drug release kinetics in swollen scleroglucan matrices.
    François NJ; Rojas AM; Daraio ME; Bernik DL
    J Control Release; 2003 Jul; 90(3):355-62. PubMed ID: 12880702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Optimization of liberation of theophylline derivatives from Gelucire matrix tablets].
    Ratsimbazafy V; Brossard C
    Pharm Acta Helv; 1992; 67(5-6):166-71. PubMed ID: 1438455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biocompatible implants for the sustained zero-order release of narcotic antagonists.
    Abrahams RA; Ronel SH
    J Biomed Mater Res; 1975 May; 9(3):355-66. PubMed ID: 1176491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A possible pH-controlled drug delivery system based on a derivative of the polysaccharide scleroglucan.
    Alhaique F; Riccieri FM; Santucci E; Crescenzi V; Gamini A
    J Pharm Pharmacol; 1985 May; 37(5):310-3. PubMed ID: 2862238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.
    Kirilmaz L; Kendirci A; Güneri T
    J Microencapsul; 1992; 9(2):167-72. PubMed ID: 1593399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crushing tablets or opening capsules: many uncertainties, some established dangers.
    Prescrire Int; 2014 Sep; 23(152):209-11, 213-4. PubMed ID: 25325120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effect of microencapsulation on the pharmacological activity of theophylline and euphylline].
    Andreeva IN; Saraf AS; Makarov VA
    Farmakol Toksikol; 1991; 54(5):27-9. PubMed ID: 1800140
    [No Abstract]   [Full Text] [Related]  

  • 51. [Preparation of oral sustained-action preparations with a base of biologically degradable polymers. 2. Preparation of matrix tablets with a base of polylactic acid].
    Mank R; Kala H; Richter M
    Pharmazie; 1989 May; 44(5):328-30. PubMed ID: 2772012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preparation and preliminary evaluation of sustained-release acetylsalicylic acid tablets.
    Jovanović M; Jokić D; Durić Z; Tasić L; Jovicić G
    Pharmazie; 1990 Nov; 45(11):869. PubMed ID: 2100344
    [No Abstract]   [Full Text] [Related]  

  • 53. Oral Modified Drug Release Solid Dosage Form with Special Reference to Design; An Overview.
    Murugesan S; Gowramma B; Lakshmanan K; Reddy Karri VVS; Radhakrishnan A
    Curr Drug Res Rev; 2020; 12(1):16-25. PubMed ID: 31755398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extemporaneously prepared controlled release formulations for accelerating the early phase development of drug candidates.
    Thombre AG; Berchielli A; Rogers JF
    Drug Discov Today; 2014 May; 19(5):694-700. PubMed ID: 24560934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of curdlan to controlled drug delivery. II. In vitro and in vivo drug release studies of theophylline-containing curdlan tablets.
    Kanke M; Katayama H; Nakamura M
    Biol Pharm Bull; 1995 Aug; 18(8):1104-8. PubMed ID: 8535404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability of starch based hot stage extrusion formulations.
    Henrist D; Lefebvre RA; Remon JP
    Int J Pharm; 1999 Oct; 187(2):185-91. PubMed ID: 10502624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formulation studies on slow-release phosphate tablets for high-dosage administration in renal transplant patients [proceedings].
    Woodroffe R
    J Pharm Pharmacol; 1976 Dec; 28 Suppl():68P. PubMed ID: 12346
    [No Abstract]   [Full Text] [Related]  

  • 58. In vitro kinetics of drug release from oral dosage forms, lyophilized and conventional rectal suppositories.
    Bhavnagri VP; Speiser P
    Pharm Acta Helv; 1976; 51(1):10-8. PubMed ID: 951423
    [No Abstract]   [Full Text] [Related]  

  • 59. Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use.
    Ainaoui A; Siepmann J; Bodmeier R; Vergnaud JM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):17-24. PubMed ID: 11154899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel co-crosslinked polysaccharide: studies for a controlled delivery matrix.
    Coviello T; Dentini M; Rambone G; Desideri P; Carafa M; Murtas E; Riccieri FM; Alhaique F
    J Control Release; 1998 Oct; 55(1):57-66. PubMed ID: 9795015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.